Surgery Partners, Inc. SGRY Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

Tenet HealthcareTHC

——

PACS GroupPACS

——

Revenue$810.9M+4.5%

Operating income$65.8M+6.3%

Net income-$35.9M+4.8%

EPS (diluted)-$0.28+6.7%

Cash & equivalents$182.3M-20.5%

Total debt$5.1B+4.6%

Total equity$1.7B-3.0%

Total assets$8.0B+1.2%

Operating cash flow$11.7M+95.0%

CapEx$16.0M-29.5%

Free cash flow-$4.3M+74.3%

Market cap$1.99B-49.1%

Gross margin23.1%—

Operating margin11.8%+1.2pp

Net margin-2.3%-0.9pp

FCF margin6.2%+0.8pp

Return on equity-4.4%-1.6pp

Debt / equity3×+0.2×

Current ratio1.9×0.0×

Reported directly by Surgery Partners, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: Surgery Partners, Inc.’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Surgery Partners, Inc.'s indefinite-lived research and development assets?: Surgery Partners, Inc. (SGRY) reported indefinite-lived research and development assets of $5.1M in Q4 2025.